Literature DB >> 2231091

Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation.

K W Erickson1, M R Costanzo-Nordin, E J O'Sullivan, M R Johnson, M J Zucker, R Pifarré, C E Lawless, J A Robinson, P J Scanlon.   

Abstract

We reviewed the transpulmonary gradient, pulmonary arterial systolic pressure, pulmonary vascular resistance (Wood units), and pulmonary vascular resistance index (Wood units X Body surface area), recorded preoperatively in 109 recipients aged 44.6 +/- 13.5 (mean +/- SD) years who underwent orthotopic heart transplantation between March 1984 and March 1988, to identify which measure of pulmonary hypertension most accurately predicts poor outcome after orthotopic heart transplantation. These recipients were followed up as many as 57 (24.7 +/- 14.5) months after their transplant procedure. Preoperative hemodynamic values were as follows: transpulmonary gradient, 10.4 +/- 4.7 mm Hg; pulmonary artery systolic pressure, 53.6 +/- 14.8 mm Hg; pulmonary vascular resistance, 2.7 +/- 1.8 Wood units; pulmonary vascular resistance index, 4.9 +/- 2.7. Nineteen recipients died within 1 year after orthotopic heart transplantation. Causes of death were acute rejection (8), chronic rejection (1), infection (2), nonspecific orthotopic heart transplant failure (4), bowel ischemia (1), pancreatitis (1), lymphoma (1), and liver failure (1). Preoperative pulmonary arterial systolic pressure, pulmonary vascular resistance, and pulmonary vascular resistance index were not predictive of 1-month, 6-month, or 1-year mortality. One-month mortality rates of orthotopic heart transplant recipients with transpulmonary gradient greater than or equal to 12 mm Hg and of those with transpulmonary gradient less than 12 mm Hg were not significantly different (11% vs 3%; p = 0.12). The 6-month mortality rate of orthotopic heart transplant recipients with transpulmonary gradient greater than or equal to 12 mm Hg, however, was five times greater than that of orthotopic heart transplant recipients with transpulmonary gradient less than 12 mm Hg (24% vs 5%; p = 0.003), and 12-month mortality of orthotopic heart transplant recipients with transpulmonary gradient greater than or equal to 12 mm Hg was increased sevenfold when compared with that of orthotopic heart transplant recipients with transpulmonary gradient less than 12 mm Hg (36% vs 5%; p = 0.0005). These results suggest that presently used measures of pulmonary hypertension do not predict mortality in the first month after orthotopic heart transplantation, but that elevated preoperative transpulmonary gradient is associated with a significant increase in mortality at 6 and 12 months after orthotopic heart transplantation. Prospective randomized trials are needed to determined whether extended preload and afterload reduction before and/or after transplant will favorably influence long-term prognosis of orthotopic heart transplant recipients with elevated preoperative transpulmonary gradient.

Entities:  

Mesh:

Year:  1990        PMID: 2231091

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  13 in total

1.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

2.  Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure.

Authors:  Amresh Raina; Talha Meeran
Journal:  Curr Heart Fail Rep       Date:  2018-04

3.  Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury.

Authors:  Todd M Bull; Brendan Clark; Kim McFann; Marc Moss
Journal:  Am J Respir Crit Care Med       Date:  2010-06-17       Impact factor: 21.405

4.  Guidelines for heart transplantation.

Authors:  N de Jonge; J H Kirkels; C Klöpping; J R Lahpor; K Caliskan; A P W M Maat; J Brügemann; M E Erasmus; R J M Klautz; H F Verwey; A Oomen; C H Peels; A E J Golüke; D Nicastia; M A C Koole; A H M M Balk
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

5.  Fall in pulmonary vascular resistance in patients awaiting heart transplantation.

Authors:  S C Grant; R D Levy; N H Brooks
Journal:  Br Heart J       Date:  1992-10

Review 6.  Sildenafil in the treatment of pulmonary hypertension.

Authors:  Christopher F Barnett; Roberto F Machado
Journal:  Vasc Health Risk Manag       Date:  2006

7.  Comparison of drugs for pulmonary hypertension reversibility testing: A meta-analysis.

Authors:  Maya Guglin; Shabnam Mehra; Thomas J Mason
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

8.  Comparison of continuous-flow ventricular assist device therapy with intensive medical therapy in fixed pulmonary hypertension secondary to advanced left heart failure.

Authors:  Gayathri Kumarasinghe; Pankaj Jain; Andrew Jabbour; Jacqueline Lai; Anne M Keogh; Eugene Kotlyar; Paul Jansz; Peter S Macdonald; Christopher S Hayward
Journal:  ESC Heart Fail       Date:  2018-03-24

9.  Detrimental effects of elevated transpulmonary gradient on outcomes following restrictive mitral annuloplasty in patients with pre-existing pulmonary hypertension.

Authors:  Satoshi Kainuma; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Hiroki Hata; Daisuke Yoshioka; Takuji Kawamura; Ai Kawamura; Noriyuki Kashiyama; Takayoshi Ueno; Toru Kuratani; Toshihiro Funatsu; Haruhiko Kondoh; Takafumi Masai; Arudo Hiraoka; Taichi Sakaguchi; Hidenori Yoshitaka; Takashi Daimon; Kazuhiro Taniguchi; Yoshiki Sawa
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

10.  Lowering pulmonary wedge pressure after heart transplant: pulmonary compliance and resistance effect.

Authors:  Nádia Moreira; Rui Baptista; Susana Costa; Fátima Franco; Mariano Pêgo; Manuel Antunes
Journal:  Arq Bras Cardiol       Date:  2015-07-31       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.